BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther. 2015;41:459-466. [PMID: 25523381 DOI: 10.1111/apt.13061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Dam G, Vilstrup H, Andersen PK, Bossen L, Watson H, Jepsen P. Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites. Liver Int 2019;39:514-21. [DOI: 10.1111/liv.14012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
2 Picardi A, Vespasiani-Gentilucci U. Proton pump inhibitor prescription abuse and sepsis in cirrhosis. World J Gastrointest Pharmacol Ther 2016; 7(1): 1-4 [PMID: 26855807 DOI: 10.4292/wjgpt.v7.i1.1] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Cole HL, Pennycook S, Hayes PC. The impact of proton pump inhibitor therapy on patients with liver disease. Aliment Pharmacol Ther 2016;44:1213-23. [DOI: 10.1111/apt.13827] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
4 Tergast TL, Wranke A, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B. Dose‐dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. Liver Int 2018;38:1602-13. [DOI: 10.1111/liv.13862] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
5 Baik SH, Fung K, Mcdonald CJ. The Mortality Risk of Proton Pump Inhibitors in 1.9 Million US Seniors: An Extended Cox Survival Analysis. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.01.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lee J, Mark RG, Celi LA, Danziger J. Proton Pump Inhibitors Are Not Associated With Acute Kidney Injury in Critical Illness. J Clin Pharmacol 2016;56:1500-6. [PMID: 27492273 DOI: 10.1002/jcph.805] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
7 Horvath A, Stadlbauer V. [Proton Pump Inhibitors and their Microbiome-Mediated Side Effects]. Zentralbl Chir 2021;146:165-9. [PMID: 33327006 DOI: 10.1055/a-1312-7587] [Reference Citation Analysis]
8 Chang TE, Huang YS, Perng CL, Huang YH, Hou MC. Use of proton pump inhibitors and the risk of hepatocellular carcinoma: A systematic review and meta-analysis. J Chin Med Assoc 2019;82:756-61. [PMID: 31335628 DOI: 10.1097/JCMA.0000000000000157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Williams MJ, Hayes P. Improving the management of gastrointestinal bleeding in patients with cirrhosis. Expert Rev Gastroenterol Hepatol 2016;10:505-15. [PMID: 26581713 DOI: 10.1586/17474124.2016.1122523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
10 Shaikh BA, Shaikh ZA, Shah AH, Kumar A. Determining the Risk of Spontaneous Bacterial Peritonitis due to increase use of Proton Pump Inhibitors among cirrhotic patients with ascites. Pak J Med Sci 2021;37:1075-9. [PMID: 34290786 DOI: 10.12669/pjms.37.4.3476] [Reference Citation Analysis]
11 Bajaj JS, Acharya C, Fagan A, White MB, Gavis E, Heuman DM, Hylemon PB, Fuchs M, Puri P, Schubert ML, Sanyal AJ, Sterling RK, Stravitz TR, Siddiqui MS, Luketic V, Lee H, Sikaroodi M, Gillevet PM. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. Am J Gastroenterol. 2018;113:1177-1186. [PMID: 29872220 DOI: 10.1038/s41395-018-0085-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 14.5] [Reference Citation Analysis]
12 Labenz C, Wörns MA, Adarkwah CC, Galle PR, Schattenberg JM, Kostev K. Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. Aliment Pharmacol Ther 2020;52:1042-50. [PMID: 32729625 DOI: 10.1111/apt.16008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Tripathi D, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, Austin A, Ferguson JW, Olliff SP, Hudson M, Christie JM;  Clinical Services and Standards Committee of the British Society of Gastroenterology. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64:1680-1704. [PMID: 25887380 DOI: 10.1136/gutjnl-2015-309262] [Cited by in Crossref: 260] [Cited by in F6Publishing: 197] [Article Influence: 37.1] [Reference Citation Analysis]
14 Li DK, Chung RT. Use of proton pump inhibitors in chronic liver diseases. Clin Liver Dis (Hoboken) 2017;10:148-51. [PMID: 30992776 DOI: 10.1002/cld.678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908 [PMID: 30833797 DOI: 10.3748/wjg.v25.i8.888] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
16 Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64:1265-1272. [PMID: 27474889 DOI: 10.1002/hep.28737] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 15.5] [Reference Citation Analysis]
17 Shi L, Zhang D. Proton Pump Inhibitor Use Before ICU Admission Is Not Associated With Mortality of Critically Ill Patients. J Clin Pharmacol 2020;60:860-6. [PMID: 32043627 DOI: 10.1002/jcph.1585] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Lázaro-Pacheco IB, Servín-Caamaño AI, Pérez-Hernández JL, Rojas-Loureiro G, Servín-Abad L, Tijera FH. PROTON PUMP INHIBITORS INCREASE THE OVERALL RISK OF DEVELOPING BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS. Arq Gastroenterol 2018;55:28-32. [PMID: 29561973 DOI: 10.1590/S0004-2803.201800000-09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wu X, Zhang D, Yu Y, Lou L, Li X. Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies. Biosci Rep 2020;40:BSR20193890. [PMID: 32406491 DOI: 10.1042/BSR20193890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, Hou MC, Lee FY, Su TP, Lu CL. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology. 2017;152:134-141. [PMID: 27639806 DOI: 10.1053/j.gastro.2016.09.007] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
21 Hung T, Tseng C, Lee H, Tsai C, Tsai C. Effect of Proton Pump Inhibitors on Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. Annals of Hepatology 2018;17:933-9. [DOI: 10.5604/01.3001.0012.7193] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Trifan A, Stoica O, Stanciu C, Cojocariu C, Singeap AM, Girleanu I, Miftode E. Clostridium difficile infection in patients with liver disease: a review. Eur J Clin Microbiol Infect Dis 2015;34:2313-24. [PMID: 26440041 DOI: 10.1007/s10096-015-2501-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
23 Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:851-66. [PMID: 32172363 DOI: 10.1007/s00228-020-02854-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
24 Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
25 Brown JP, Tazare JR, Williamson E, Mansfield KE, Evans SJ, Tomlinson LA, Bhaskaran K, Smeeth L, Wing K, Douglas IJ. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study. Br J Clin Pharmacol 2021;87:3150-61. [PMID: 33393677 DOI: 10.1111/bcp.14728] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
27 Yu T, Tang Y, Jiang L, Zheng Y, Xiong W, Lin L. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis. Dig Liver Dis. 2016;48:353-359. [PMID: 26795544 DOI: 10.1016/j.dld.2015.12.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
28 Janka T, Tornai T, Borbély B, Tornai D, Altorjay I, Papp M, Vitális Z. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis. Eur J Gastroenterol Hepatol 2020;32:257-64. [PMID: 31464790 DOI: 10.1097/MEG.0000000000001499] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
29 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
30 Singh A, Garg R, Lan N, Siddiqui MT, Gupta M, Alkhouri N. Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease. Indian J Gastroenterol 2020;39:591-8. [DOI: 10.1007/s12664-020-01087-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Hov JR. Editorial: proton pump inhibition - microbial complications beyond dysbiosis. Aliment Pharmacol Ther 2019;50:962-3. [PMID: 31591776 DOI: 10.1111/apt.15495] [Reference Citation Analysis]
32 Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, Metselaar HJ, Monster-Simons MH, van Putten SAW, Taxis K, Borgsteede SD. Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018;84:1806-1820. [PMID: 29688583 DOI: 10.1111/bcp.13615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
33 Min YW, Kang D, Shin JY, Kang M, Park JK, Lee KH, Lee JK, Lee KT, Rhee PL, Kim JJ, Guallar E, Cho J, Lee H. Use of proton pump inhibitors and the risk of cholangitis: a nationwide cohort study. Aliment Pharmacol Ther. 2019;50:760-768. [PMID: 31448440 DOI: 10.1111/apt.15466] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
34 Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology. 2018;. [PMID: 30289992 DOI: 10.1002/hep.30304] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 11.3] [Reference Citation Analysis]
35 Horvath A, Rainer F, Bashir M, Leber B, Schmerboeck B, Klymiuk I, Groselj-Strele A, Durdevic M, Freedberg DE, Abrams JA, Fickert P, Stiegler P, Stadlbauer V. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. Sci Rep. 2019;9:12000. [PMID: 31427714 DOI: 10.1038/s41598-019-48352-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
36 Komori K, Kubokawa M, Ihara E, Akahoshi K, Nakamura K, Motomura K, Masumoto A. Prognostic factors associated with mortality in patients with gastric fundal variceal bleeding. World J Gastroenterol 2017; 23(3): 496-504 [PMID: 28210086 DOI: 10.3748/wjg.v23.i3.496] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
37 Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: Risks of long-term use: Proton pump inhibitors. Journal of Gastroenterology and Hepatology 2017;32:1295-302. [DOI: 10.1111/jgh.13737] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 15.4] [Reference Citation Analysis]
38 Ghoz H, Patel P, Stancampiano F, Patel S, Fox EA, Yousaf MB, Omer M, Heckman MG, Spiegel MR, Palmer WC. Proton-pump-inhibitor use associated with lower short-term rebleeding and mortality in patients receiving esophageal variceal band ligation: a retrospective cohort study. Eur J Gastroenterol Hepatol 2020;32:1571-8. [PMID: 32868651 DOI: 10.1097/MEG.0000000000001905] [Reference Citation Analysis]
39 Martynov AI, Sheptulin AA, Mayev IV, Kazyulin AN, Karateev AY, Melekhov AV, Pal’gova LK, Raikhel’son KL. New Prospects of Cytoprotection in the Treatment and Prevention of Gastric and Intestinal Diseases (Resolution of an Expert Council and Literature Review). Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:7-14. [DOI: 10.22416/1382-4376-2020-30-2-7-14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
40 Labenz C, Kostev K, Galle PR, Wörns MA, Labenz J, Tanislav C, Adarkwah CC. Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis. Medicine (Baltimore) 2020;99:e23436. [PMID: 33327272 DOI: 10.1097/MD.0000000000023436] [Reference Citation Analysis]
41 Hung T, Lee H, Tseng C, Tsai C, Tsai C. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding. Clinics and Research in Hepatology and Gastroenterology 2018;42:353-9. [DOI: 10.1016/j.clinre.2017.11.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
42 Tantai XX, Yang LB, Wei ZC, Xiao CL, Chen LR, Wang JH, Liu N. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol 2019; 25(21): 2683-2698 [PMID: 31210719 DOI: 10.3748/wjg.v25.i21.2683] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
43 Shaw J, Bajaj JS. Editorial: should the inappropriate use of proton pump inhibitors be a quality assurance issue in cirrhotic patients? Aliment Pharmacol Ther 2017;45:476-7. [PMID: 28043093 DOI: 10.1111/apt.13875] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
44 Wang AJ, Wang J, Zheng XL, Liao WD, Yu HQ, Gong Y, Gan N, You Y, Guo GH, Xie BS, Zhong JW, Hong JB, Liu L, Shu X, Zhu Y, Li BM, Zhu X. Second‐look endoscopy‐guided therapy under sedation prevents early rebleeding after variceal ligation for acute variceal bleeding. J Dig Dis 2020;21:170-8. [DOI: 10.1111/1751-2980.12847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Lanas-gimeno A, Hijos G, Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opinion on Drug Safety 2019;18:1043-53. [DOI: 10.1080/14740338.2019.1664470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
46 Farhat N, Fortin Y, Haddad N, Birkett N, Mattison DR, Momoli F, Wu Wen S, Krewski D. Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents. Critical Reviews in Toxicology 2019;49:215-61. [DOI: 10.1080/10408444.2019.1583167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
47 Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxis. World J Crit Care Med 2016; 5(1): 57-64 [PMID: 26855894 DOI: 10.5492/wjccm.v5.i1.57] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
48 Hung TH, Tseng CW, Tsai CC, Lee HF. Effect of proton pump inhibitors on mortality of cirrhotic patients with pneumonia. PLoS One 2019;14:e0216041. [PMID: 31022265 DOI: 10.1371/journal.pone.0216041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Schiavon LL, Silva TE, Fischer J, Narciso-Schiavon JL. Letter: Proton pump inhibitors and prognosis of cirrhosis - searching for the balance point. Aliment Pharmacol Ther. 2017;45:378-379. [PMID: 27933687 DOI: 10.1111/apt.13873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
50 Sutherland D, Stanley AJ. Editorial: proton pump inhibitors in cirrhosis. Aliment Pharmacol Ther 2015;41:592-592. [DOI: 10.1111/apt.13089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Sakamaki A, Kamimura K, Yokoo T, Osaki A, Yoshikawa S, Arao Y, Setsu T, Kamimura H, Waguri N, Takeuchi M, Funakoshi K, Terai S. The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan. Medicine (Baltimore) 2021;100:e26902. [PMID: 34397919 DOI: 10.1097/MD.0000000000026902] [Reference Citation Analysis]
52 Li DK, Yan P, Abou-Samra AB, Chung RT, Butt AA. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Aliment Pharmacol Ther 2018;47:246-58. [PMID: 29105111 DOI: 10.1111/apt.14391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
53 Martinsen TC, Fossmark R, Waldum HL. The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid. Int J Mol Sci 2019;20:E6031. [PMID: 31795477 DOI: 10.3390/ijms20236031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
54 Drolz A, Schramm C, Seiz O, Groth S, Vettorazzi E, Horvatits T, Wehmeyer MH, Schramm C, Goeser T, Roesch T, Lohse AW, Kluwe J. Risk factors associated with bleeding after prophylactic endoscopic variceal ligation in cirrhosis. Endoscopy 2021;53:226-34. [DOI: 10.1055/a-1214-5355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]